Answers are grounded in this paper and cite their sources.
Immune-related adverse event subacute cutaneous lupus erythematosus (irAE-SCLE) is a rare toxicity of immune checkpoint inhibitor (ICI) therapy that may necessitate discontinuation of life-prolonging cancer treatment. The biological mechanisms underlying the pathogenesis of irAE-SCLE and how these differ from non-irAE SCLE remain poorly understood. Here, we report a patient with advanced melanoma who developed grade IV irAE-SCLE requiring hospitalization following two independent courses of anti-programmed death-1 therapy, resulting in treatment cessation on both occasions. We profiled one skin biopsy from each of the two irAE-SCLE episodes in the same patient, along with four normal skin samples from four independent patients and three non-irAE SCLE samples from two additional patients, using single-cell spatial transcriptomics. Both irAE-SCLE and non-irAE SCLE exhibited increased interferon (IFN) signaling relative to normal skin; however, IFN activity was substantially lower in irAE-SCLE. Non-irAE SCLE lesions contained prominent CXCL9-expressing, CXCL10-expressing, and CXCL11-expressing inflammatory niches that were absent in irAE-SCLE, while irAE-SCLE exhibited a reduced lymphoid-to-myeloid cell ratio within the superficial dermal infiltrate. In addition, irAE-SCLE lesions were enriched for hypoxia-associated and extracellular matrix remodeling programs that may contribute to the severe blistering phenotype. Together, these findings identify biological differences between irAE-SCLE and non-irAE SCLE and suggest that distinct inflammatory and tissue-remodeling programs contribute to irAE-SCLE pathogenesis.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: